GENE ONLINE|News &
Opinion
Blog

2021-10-12| M&A

Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas

by Rajaneesh K. Gopinath
Share To
On October 11th, Maryland-based Supernus Pharmaceuticals announced that it is acquiring Adamas Pharmaceuticals in an all-cash deal amounting to approximately $400 million. This roughly comes out to $9.10 per share, which includes an upfront payment of $8.10 per share.

An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!